ペンシルベニアにおける膠腫の臨床試験
ペンシルベニア内の拠点で、膠腫に関する19件の研究が参加者を募集しています。
ペンシルベニア内の都市
公式研究テキスト（英語）
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Geisinger Medical Center, Danville
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- 他1件
被験者募集中第1/2相
12 Months – 21 Years · 全性別 · 2026/10/01更新 · NCT05099003Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07326566A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
被験者募集中第1/2相
25歳以下 · 全性別 · 2026/09/25更新 · NCT04094610Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
- The Children s Hospital of Philadelphia, Philadelphia
被験者募集中早期第1相
1歳〜21歳 · 全性別 · 2026/09/22更新 · NCT05555550ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Children's Hospital of Philidelphia, Philidelphia
被験者募集中第2相
12 Months – 39 Years · 全性別 · 2026/09/21更新 · NCT06838676Targeted Pediatric High-Grade Glioma Therapy
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中観察研究
12 Months – 39 Years · 全性別 · 2026/09/08更新 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中第2相
12歳〜39歳 · 全性別 · 2026/09/01更新 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中第2相
3歳〜39歳 · 全性別 · 2026/08/24更新 · NCT05096481Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中第1相
1歳〜25歳 · 全性別 · 2026/08/18更新 · NCT04485559A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Thomas Jefferson University, Philadelphia
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
- Lehigh Valley Health Network (Data Collection Only), Allentown
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05188508Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中第1/2相
4歳〜39歳 · 全性別 · 2026/07/20更新 · NCT05278208Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中早期第1相健康なボランティア歓迎
1歳〜21歳 · 全性別 · 2026/06/29更新 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中第2相
12 Months – 39 Years · 全性別 · 2026/05/29更新 · NCT05843253A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/20更新 · NCT06326411A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中早期第1相
21歳以下 · 全性別 · 2026/03/18更新 · NCT04655404All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
- University of Pennsylvania, Philadelphia
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/20更新 · NCT0534500218F-Fluciclovine PET-MRI in High-grade Glioma
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中早期第1相
1歳〜21歳 · 全性別 · 2025/12/04更新 · NCT05553041ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。